Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

PubMed  Google Scholar 

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science. 1987;235(4785):177–82.

Article  CAS  PubMed  Google Scholar 

Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, et al. Antibody–maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 2006;66(8):4426–33.

Article  CAS  PubMed  Google Scholar 

Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6(4):443–6.

Article  CAS  PubMed  Google Scholar 

von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–28.

Article  Google Scholar 

Diéras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J, et al. Trastuzumab emtansine in human epidermal growth factor receptor 2–positive metastatic breast cancer: an integrated safety analysis. Lancet Oncol. 2014;15(7):689–99.

Google Scholar 

Kadcyla (trastuzumab emtansine) [package insert]. South San Francisco, CA: Genentech, Inc; 2023.

Urruticoechea A, Rizwanullah M, Im SA, Ruiz-Borrego M, Perez-Garcia JM, Cortes J. Safety and bleeding outcomes with trastuzumab emtansine: a real-world analysis. Breast Cancer Res Treat. 2020;181(2):359–67.

Google Scholar 

De Luca A, Maiello E, D’Alonzo A, Rizzo P, Malorni L. Telangiectasia and mucosal bleeding associated with trastuzumab emtansine therapy. Clin Breast Cancer. 2021;21(5):e489–93.

Google Scholar 

Friedman CF, Postow MA, Chapman PB. Delayed vascular toxicities associated with antibody–drug conjugates. Oncologist. 2022;27(3):e252–60.

Google Scholar 

Ansary AM, Vadhan-Raj S, Zhao W, et al. Effect of ado-trastuzumab emtansine on autologous platelet kinetics and function. J Clin Oncol. 2022;40(36):4173–83. https://doi.org/10.1200/JCO.22.00441.

Article  Google Scholar 

Mojardín L, Botella LM, Vera J, Valdés-Mora F, Arribas J. HER2 expression in endothelial cells and implications for antibody–drug conjugate toxicity. J Transl Med. 2020;18(1):324.

Google Scholar 

Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Clin Oncol. 2007;25(28):4341–7.

Google Scholar 

Friedman CF, Postow MA, Chapman PB. Delayed vascular toxicities of antibody–drug conjugates. Oncologist. 2022;27(3):e252–60 (Used where delayed/persistent toxicity is discussed).

Google Scholar 

Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med. 2000;342(17):1266–71.

Article  CAS  PubMed  Google Scholar 

Sibaud V, Niec RE, Schindler K, Busam KJ, Roché H, Modi S, et al. Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series. Breast Cancer Res Treat. 2014;146(2):451–6. https://doi.org/10.1007/s10549-014-3001-z.

Article  PubMed  Google Scholar 

Kwon Y, Gomberg-Maitland M, Pritzker M, Thenappan T. Telangiectasia and pulmonary arterial hypertension following treatment with trastuzumab emtansine: a case report. Chest. 2016;149(4):e103–5. https://doi.org/10.1016/j.chest.2015.09.008.

Article  PubMed  Google Scholar 

Gursoy P, Acar A, Acikalin T. Ado-trastuzumab emtansine–associated spider telangiectasia. J Oncol Pharm Pract. 2022;28(4):986–8. https://doi.org/10.1177/10781552211073878.

Article  CAS  PubMed  Google Scholar 

Tyburec M, Braslavsky A, Serrano C, Vázquez C, Serra M. Management of hereditary hemorrhagic telangiectasia-like symptoms induced by trastuzumab emtansine in a breast cancer patient: a case report. J Chemother. 2025;37(4):383–7. https://doi.org/10.1080/1120009X.2024.2379169.

Article  CAS  PubMed  Google Scholar